AGARWALEYE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.6
| Stock Code | AGARWALEYE | Market Cap | 13,428 Cr. | Current Price | 424 ₹ | High / Low | 568 ₹ |
| Stock P/E | 228 | Book Value | 61.8 ₹ | Dividend Yield | 0.00 % | ROCE | 5.94 % |
| ROE | 1.31 % | Face Value | 1.00 ₹ | DMA 50 | 454 ₹ | DMA 200 | 459 ₹ |
| Chg in FII Hold | -0.07 % | Chg in DII Hold | -0.14 % | PAT Qtr | 14.6 Cr. | PAT Prev Qtr | 4.95 Cr. |
| RSI | 36.7 | MACD | -7.96 | Volume | 1,78,356 | Avg Vol 1Wk | 1,78,929 |
| Low price | 327 ₹ | High price | 568 ₹ | PEG Ratio | 1.49 | Debt to equity | 0.30 |
| 52w Index | 40.0 % | Qtr Profit Var | 80.3 % | EPS | 1.75 ₹ | Industry PE | 43.5 |
📊 Agarwal Eye Hospital (AGARWALEYE) shows weak intraday potential today. RSI at 36.7 indicates oversold conditions but lacks strong reversal signals. MACD is negative (-7.96), confirming bearish sentiment. Current price (424 ₹) is below both 50 DMA (454 ₹) and 200 DMA (459 ₹), reflecting short-term weakness. Volume (1,78,356) is nearly equal to average (1,78,929), suggesting limited volatility for intraday trading.
💡 Optimal Buy Price: 420–425 ₹ (near support)
🎯 Profit-Taking Levels: 440–450 ₹ (short-term resistance)
🛑 Stop-Loss: 410 ₹ (recent low)
⏳ If already holding intraday: Exit near 440–445 ₹ if momentum weakens or if price fails to sustain above 425 ₹ with volume confirmation.
Positive
- Quarterly PAT improved from 4.95 Cr. to 14.6 Cr. (+80.3%).
- 52-week performance is strong (+40%).
- PEG ratio of 1.49 suggests reasonable valuation relative to growth.
Limitation
- Stock trading below both 50 DMA and 200 DMA indicates bearish trend.
- Extremely high P/E (228) compared to industry average (43.5), suggesting overvaluation.
- Weak ROCE (5.94%) and ROE (1.31%) show poor efficiency.
- High debt-to-equity ratio (0.30) raises financial risk.
- FII (-0.07%) and DII (-0.14%) holdings decreased, showing reduced institutional confidence.
Company Negative News
- No major negative news reported, but weak fundamentals and high leverage weigh on sentiment.
Company Positive News
- Quarterly PAT growth indicates improving profitability.
- Strong 52-week performance highlights investor interest.
Industry
- Industry P/E at 43.5 is much lower than Agarwal Eye’s 228, suggesting relative overvaluation.
- Healthcare sector remains growth-oriented, supported by rising demand but faces margin pressures.
Conclusion
⚠️ Agarwal Eye Hospital is not an ideal intraday candidate today due to weak momentum, stretched valuations, and price trading below key averages. Short-term traders may attempt a bounce trade near 420–425 ₹ with a tight stop-loss at 410 ₹, but risk remains elevated. Conservative traders should avoid aggressive intraday positions until momentum indicators improve.